UCLA
UCLA, University College London Advancing Immune Disorder Gene Therapy Toward FDA Submission
Premium
Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially market the gene therapy for ADA-SCID.
Lyell Immunopharma to Acquire ImmPact Bio, Discontinue Several Pipeline Programs
The firm will stop developing several of its own cell therapies to focus on advancing IMPT-314, a CAR T-cell therapy it is gaining by purchasing ImmPact.
UCLA, Parker Institute for Cancer Immunotherapy Renew Research Alliance
Academic researchers' efforts to advance CAR T-cell immunotherapy research in this partnership recently received a boost from PICI.
TORL BioTherapeutics' CLDN6-Targeting Antibody-Drug Conjugate Demonstrates Encouraging Early Results
Premium
Phase I data presented at ESMO suggested that TORL-1-23 may have particularly strong activity in CLDN-positive advanced ovarian cancer.
UCLA Receives $1.8M NIH Grant to Validate Radiation Side Effect Biomarkers in Prostate Cancer
The researchers aim to validate a previously identified biomarker, called PROSTOX, that can predict urinary issues after radiation therapy.
Feb 22, 2024
Jun 28, 2019